Federal Supply Schedule 36F79719D0247
Award Date
9/15/19
Last Date to Order
9/14/25
Federal Agency
Veterans Integrated Service Network 12
Awardee
Ucb, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
The Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Viela Bio, Inc. for the delivery of Uplizna. With a potential value of $4,348,680, the BPA has a period of performance through December 28, 2020. Under this agreement, Viela Bio will provide the drug Uplizna to treat neuromyelitis optica spectrum disorder, a rare inflammatory disease of the central nervous system. The Department of Veterans Affairs procures pharmaceuticals...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Viela Bio, Inc. for the pharmaceutical Uplizna. With a potential value of $4,348,680, the single award BPA has a period of performance through May 5, 2022 and was awarded on January 12, 2021. The BPA was established against the Pharmaceuticals and Drugs GSA schedule to provide Uplizna, which is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patients...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple-award Federal Supply Schedule (FSS) contract to Albireo Pharma, Inc., a for-profit manufacturer of pharmaceuticals and drugs. The $225,000 contract, under the Pharmaceuticals and Drugs GSA Schedule, allows the VA's Veterans Integrated Service Network 12 to order various pharmaceutical products from Albireo Pharma over a 5-year period of performance from March 2022 to March 2027. Additionally, the VA National Acquisition Center...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded Lundbeck LLC a 5-year Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with a potential value of $124 million. Through this contract vehicle, the VA and other federal agencies can procure Lundbeck's portfolio of medications used to treat neurological conditions prevalent among veterans, including Sabril (vigabatrin) for treatment-resistant seizures, Xenazine (tetrabenazine) for chorea...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Lundbeck LLC, a global pharmaceutical company, to provide specialized drugs and therapies to treat disorders of the central nervous system. The contract has a ceiling value of $31,500,000 and a period of performance from January 31, 2020 to January 30, 2025, with one-year option periods. The specific drugs being procured under this BPA are Sabril (vigabatrin) for...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36F79719D0247-36E79723A0004 | Ucb, Inc. | $609.1m | 10/20/22 | 11/14/22 | 11/14/22 | |
36F79719D0247-36E79724A0006 | Ucb, Inc. | $264.3k | 2/27/24 | 2/26/26 | 1/16/25 |
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order 36F79719D0247-36C26025F0033 | Ucb, Inc. | $370.1k | 10/25/24 | 10/24/25 | 10/1/24 | |
Delivery Order 36F79719D0247-36C26024F0587 | Ucb, Inc. | $92.5k | 8/15/24 | 10/15/24 | 4/3/25 | |
Delivery Order 36F79719D0247-36C26024F0563 | Ucb, Inc. | $0 | 8/7/24 | 11/5/24 | 9/17/24 |